is a chronic and inherited bleeding disorder that affects approximately 5,000 people in the U.
Visit Hemophilia Treatment Market by Drug Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination, Recombinant Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination), Indication Type (Acquired Hemophilia, Hemophilia A, Hemophilia B
, Hemophilia C), and Distribution Channel (E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021 at https://www.
In this case report, the difficulties in treatment of an infant with severe hemophilia B
who developed antibody and allergic reaction against FIX treatment have been discussed.
The report provides a snapshot of the global therapeutic landscape of Hemophilia B
Early identification of canine hemophilia A, hemophilia B
and von Willebrand disease (VWD), a severe bleeding defect.
53%) were hemophila A & hemophilia B
respectively, and 6 (2.
5 Hemophilia B
is often a debilitating, chronic disease with complications that include bleeding episodes, hemophilic arthropathy (bleeding into a joint) and hospitalization.
As part of Wyeth's agreement with France-based Nautilus Biotech, the latter company will apply its proprietary technology to improve the action of recombinant hemophilia B
Relief from this inherited clotting disorder, hemophilia B
, has now come a step closer, thanks to gene therapy performed on a unique group of hemophiliac dogs.
Depending on the critical clotting factor missing, the disorder is identified as Hemophilia A, Hemophilia B
, Von Willebrand Disease, or another rarer condition.
The US will have the largest proportion of diagnosed prevalent cases of hemophilia A and hemophilia B
in the 9MM in 2024 at 29.
This week, a scientific team reports using gene therapy to treat dogs with a canine version of hemophilia B
, an inherited bleeding disease that afflicts one of every 30,000 persons.